APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Drugs

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

Selected research

Market Outlook & Growth Opportunities

Global Oncology Drugs Market Outlook and Growth Opportunities 2026

20 December 2025211 pages

Choose your research edition.

Industry ResearchOncology Drugs Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Read the full market overview

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

This report provides an overview of the global Oncology Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncology Drugs market.

Oncology Drugs Segment by Company

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Oncology Drugs Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Oncology Drugs Segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncology Drugs key companies, revenue, market share, and recent developments.

3. To split the Oncology Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncology Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Drugs industry.

Chapter 3: Detailed analysis of Oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncology Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Drugs Industry Trends Table 2. Oncology Drugs Industry Drivers Table 3. Oncology Drugs Industry Opportunities and Challenges Table 4. Oncology Drugs Industry Restraints Table 5. Global Oncology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Drugs Revenue Share by Company (2021-2026) Table 7. Global Oncology Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncology Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Oncology Drugs Company, Product Type & Application Table 10. Global Oncology Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chemotherapy Table 15. Significant Companies of Targeted Therapy Table 16. Significant Companies of Immunotherapy (Biologic Therapy) Table 17. Significant Companies of Hormonal Therapy Table 18. Significant Companies of Others Table 19. Global Oncology Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Oncology Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Oncology Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Oncology Drugs Sales Value Share by Type (2021-2026) Table 23. Global Oncology Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Blood Cancer Table 25. Significant Companies of Breast Cancer Table 26. Significant Companies of Gastrointestinal Cancer Table 27. Significant Companies of Prostate Cancer Table 28. Significant Companies of Respiratory or Lung Cancer Table 29. Significant Companies of Others Table 30. Global Oncology Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncology Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Oncology Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Oncology Drugs Sales Value Share by Application (2021-2026) Table 34. Global Oncology Drugs Sales Value Share by Application (2027-2032) Table 35. Global Oncology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Oncology Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Oncology Drugs Sales Value Share by Region (2021-2026) Table 38. Global Oncology Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Oncology Drugs Sales Value Share by Region (2027-2032) Table 40. Global Oncology Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Oncology Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Oncology Drugs Sales Value Market Share by Country (2021-2026) Table 43. Global Oncology Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Oncology Drugs Sales Value Market Share by Country (2027-2032) Table 45. Roche Company Information Table 46. Roche Business Overview Table 47. Roche Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Roche Oncology Drugs Product Portfolio Table 49. Roche Recent Development Table 50. Celgene Company Information Table 51. Celgene Business Overview Table 52. Celgene Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Celgene Oncology Drugs Product Portfolio Table 54. Celgene Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Novartis Oncology Drugs Product Portfolio Table 59. Novartis Recent Development Table 60. Bristol-Myers Squibb Company Information Table 61. Bristol-Myers Squibb Business Overview Table 62. Bristol-Myers Squibb Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Bristol-Myers Squibb Oncology Drugs Product Portfolio Table 64. Bristol-Myers Squibb Recent Development Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Oncology Drugs Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Merck & Co. Company Information Table 71. Merck & Co. Business Overview Table 72. Merck & Co. Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck & Co. Oncology Drugs Product Portfolio Table 74. Merck & Co. Recent Development Table 75. AstraZeneca Company Information Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AstraZeneca Oncology Drugs Product Portfolio Table 79. AstraZeneca Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Oncology Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. Amgen Company Information Table 86. Amgen Business Overview Table 87. Amgen Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Amgen Oncology Drugs Product Portfolio Table 89. Amgen Recent Development Table 90. Eli Lilly Company Information Table 91. Eli Lilly Business Overview Table 92. Eli Lilly Oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Eli Lilly Oncology Drugs Product Portfolio Table 94. Eli Lilly Recent Development Table 95. AbbVie Company Information Table 96. AbbVie Business Overview Table 97. AbbVie Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 98. AbbVie Oncology Drugs Product Portfolio Table 99. AbbVie Recent Development Table 100. Takeda Company Information Table 101. Takeda Business Overview Table 102. Takeda Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 103. Takeda Oncology Drugs Product Portfolio Table 104. Takeda Recent Development Table 105. Astellas Company Information Table 106. Astellas Business Overview Table 107. Astellas Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 108. Astellas Oncology Drugs Product Portfolio Table 109. Astellas Recent Development Table 110. Ipsen Company Information Table 111. Ipsen Business Overview Table 112. Ipsen Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 113. Ipsen Oncology Drugs Product Portfolio Table 114. Ipsen Recent Development Table 115. Sanofi Company Information Table 116. Sanofi Business Overview Table 117. Sanofi Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 118. Sanofi Oncology Drugs Product Portfolio Table 119. Sanofi Recent Development Table 120. Bayer Company Information Table 121. Bayer Business Overview Table 122. Bayer Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 123. Bayer Oncology Drugs Product Portfolio Table 124. Bayer Recent Development Table 125. Biogen Idec Company Information Table 126. Biogen Idec Business Overview Table 127. Biogen Idec Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 128. Biogen Idec Oncology Drugs Product Portfolio Table 129. Biogen Idec Recent Development Table 130. Teva Company Information Table 131. Teva Business Overview Table 132. Teva Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 133. Teva Oncology Drugs Product Portfolio Table 134. Teva Recent Development Table 135. Otsuka Company Information Table 136. Otsuka Business Overview Table 137. Otsuka Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 138. Otsuka Oncology Drugs Product Portfolio Table 139. Otsuka Recent Development Table 140. Eisai Company Information Table 141. Eisai Business Overview Table 142. Eisai Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 143. Eisai Oncology Drugs Product Portfolio Table 144. Eisai Recent Development Table 145. Merck KGaA Company Information Table 146. Merck KGaA Business Overview Table 147. Merck KGaA Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 148. Merck KGaA Oncology Drugs Product Portfolio Table 149. Merck KGaA Recent Development Table 150. Gilead Sciences Company Information Table 151. Gilead Sciences Business Overview Table 152. Gilead Sciences Oncology Drugs Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 153. Gilead Sciences Oncology Drugs Product Portfolio Table 154. Gilead Sciences Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Oncology Drugs Product Image Figure 2. Global Oncology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chemotherapy Image Figure 8. Targeted Therapy Image Figure 9. Immunotherapy (Biologic Therapy) Image Figure 10. Hormonal Therapy Image Figure 11. Others Image Figure 12. Global Oncology Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Oncology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Oncology Drugs Sales Value Share by Type (2021-2032) Figure 15. Blood Cancer Image Figure 16. Breast Cancer Image Figure 17. Gastrointestinal Cancer Image Figure 18. Prostate Cancer Image Figure 19. Respiratory or Lung Cancer Image Figure 20. Others Image Figure 21. Global Oncology Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oncology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Oncology Drugs Sales Value Share by Application (2021-2032) Figure 24. Global Oncology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Oncology Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. North America Oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. South America Oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
Applications
  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory or Lung Cancer
  • Others
Companies covered
  • Roche
  • Celgene
  • Novartis
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co.
  • AstraZeneca
  • Pfizer
  • Amgen
  • Eli Lilly
  • AbbVie
  • Takeda
  • Astellas
  • Ipsen
  • Sanofi
  • Bayer
  • Biogen Idec
  • Teva
  • Otsuka
  • Eisai
  • Merck KGaA
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncology Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncology Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncology Drugs Market Dynamics
  1. 2.1 Oncology Drugs Industry Trends
  2. 2.2 Oncology Drugs Industry Drivers
  3. 2.3 Oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Oncology Drugs Industry Restraints
3 Oncology Drugs Market by Company
  1. 3.1 Global Oncology Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Drugs Company Ranking (2024-2026)
  4. 3.4 Global Oncology Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncology Drugs Company Product Type and Application
  6. 3.6 Global Oncology Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncology Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncology Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncology Drugs Market by Type
  1. 4.1 Oncology Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Immunotherapy (Biologic Therapy)
  5. 4.1.4 Hormonal Therapy
  6. 4.1.5 Others
  7. 4.2 Global Oncology Drugs Sales Value by Type
  8. 4.2.1 Global Oncology Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncology Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Oncology Drugs Sales Value Share by Type (2021-2032)
5 Oncology Drugs Market by Application
  1. 5.1 Oncology Drugs Application Introduction
  2. 5.1.1 Blood Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Gastrointestinal Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Respiratory or Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global Oncology Drugs Sales Value by Application
  9. 5.2.1 Global Oncology Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Oncology Drugs Sales Value by Application (2021-2032)
  11. 5.2.3 Global Oncology Drugs Sales Value Share by Application (2021-2032)
6 Oncology Drugs Regional Value Analysis
  1. 6.1 Global Oncology Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncology Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncology Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncology Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Oncology Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncology Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Oncology Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncology Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncology Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncology Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Oncology Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncology Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncology Drugs Sales Value Share by Country, 2025 VS 2032
7 Oncology Drugs Country-level Value Analysis
  1. 7.1 Global Oncology Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncology Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncology Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncology Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncology Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncology Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncology Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncology Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncology Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncology Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncology Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncology Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncology Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncology Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncology Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncology Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncology Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncology Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncology Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncology Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncology Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncology Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncology Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncology Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncology Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncology Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncology Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncology Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncology Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncology Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncology Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncology Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncology Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncology Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Oncology Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Oncology Drugs Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Celgene
  8. 8.2.1 Celgene Company Information
  9. 8.2.2 Celgene Business Overview
  10. 8.2.3 Celgene Oncology Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Celgene Oncology Drugs Product Portfolio
  12. 8.2.5 Celgene Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Oncology Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Oncology Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Oncology Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Merck & Co.
  32. 8.6.1 Merck & Co. Company Information
  33. 8.6.2 Merck & Co. Business Overview
  34. 8.6.3 Merck & Co. Oncology Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co. Oncology Drugs Product Portfolio
  36. 8.6.5 Merck & Co. Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Oncology Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Oncology Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Oncology Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Oncology Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Oncology Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Oncology Drugs Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Oncology Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Oncology Drugs Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 AbbVie
  62. 8.11.1 AbbVie Company Information
  63. 8.11.2 AbbVie Business Overview
  64. 8.11.3 AbbVie Oncology Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AbbVie Oncology Drugs Product Portfolio
  66. 8.11.5 AbbVie Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Oncology Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Oncology Drugs Product Portfolio
  72. 8.12.5 Takeda Recent Developments
  73. 8.13 Astellas
  74. 8.13.1 Astellas Company Information
  75. 8.13.2 Astellas Business Overview
  76. 8.13.3 Astellas Oncology Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Oncology Drugs Product Portfolio
  78. 8.13.5 Astellas Recent Developments
  79. 8.14 Ipsen
  80. 8.14.1 Ipsen Company Information
  81. 8.14.2 Ipsen Business Overview
  82. 8.14.3 Ipsen Oncology Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ipsen Oncology Drugs Product Portfolio
  84. 8.14.5 Ipsen Recent Developments
  85. 8.15 Sanofi
  86. 8.15.1 Sanofi Company Information
  87. 8.15.2 Sanofi Business Overview
  88. 8.15.3 Sanofi Oncology Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Oncology Drugs Product Portfolio
  90. 8.15.5 Sanofi Recent Developments
  91. 8.16 Bayer
  92. 8.16.1 Bayer Company Information
  93. 8.16.2 Bayer Business Overview
  94. 8.16.3 Bayer Oncology Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bayer Oncology Drugs Product Portfolio
  96. 8.16.5 Bayer Recent Developments
  97. 8.17 Biogen Idec
  98. 8.17.1 Biogen Idec Company Information
  99. 8.17.2 Biogen Idec Business Overview
  100. 8.17.3 Biogen Idec Oncology Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biogen Idec Oncology Drugs Product Portfolio
  102. 8.17.5 Biogen Idec Recent Developments
  103. 8.18 Teva
  104. 8.18.1 Teva Company Information
  105. 8.18.2 Teva Business Overview
  106. 8.18.3 Teva Oncology Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Teva Oncology Drugs Product Portfolio
  108. 8.18.5 Teva Recent Developments
  109. 8.19 Otsuka
  110. 8.19.1 Otsuka Company Information
  111. 8.19.2 Otsuka Business Overview
  112. 8.19.3 Otsuka Oncology Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Otsuka Oncology Drugs Product Portfolio
  114. 8.19.5 Otsuka Recent Developments
  115. 8.20 Eisai
  116. 8.20.1 Eisai Company Information
  117. 8.20.2 Eisai Business Overview
  118. 8.20.3 Eisai Oncology Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Eisai Oncology Drugs Product Portfolio
  120. 8.20.5 Eisai Recent Developments
  121. 8.21 Merck KGaA
  122. 8.21.1 Merck KGaA Company Information
  123. 8.21.2 Merck KGaA Business Overview
  124. 8.21.3 Merck KGaA Oncology Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Merck KGaA Oncology Drugs Product Portfolio
  126. 8.21.5 Merck KGaA Recent Developments
  127. 8.22 Gilead Sciences
  128. 8.22.1 Gilead Sciences Company Information
  129. 8.22.2 Gilead Sciences Business Overview
  130. 8.22.3 Gilead Sciences Oncology Drugs Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Gilead Sciences Oncology Drugs Product Portfolio
  132. 8.22.5 Gilead Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst